Preliminary NICE no for Tyverb and Herceptin in breast cancer
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is poised to reject for use on the NHS GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab) when used in combination with an aromatase inhibitor to treat metastatic hormone-receptor and HER2 positive breast cancer.